Phase 3 N=388 A Clinical Trial of Lurasidone in Treatment of Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores. — -31.2; -34.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=115 Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)
Anesthesia, General
Primary: Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration — 4.35; 7.15 Minutes
Phase 3 N=81 Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
Autistic Disorder
Primary: Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase — 25.5; 18.6 units on a scale
Phase 3 N=196 MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
Spasticity
Primary: MAS(Modified Ashworth Scale) of Wrist Flexor — 2.41; 2.52; 1.02; 0.96 Scores on a MAS Scale — p=0.1347
Phase 3 N=284 Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
Neisseria Meningitidis · Bacterial Infections · Virus Diseases
Primary: Percentage of Participants With Anti-Meningococcal Serogroup C (Anti-MCC) Antibody (Ab) Titre ≥1:8 Dil One Month After MCC-TT or MCC-CRM (Part 1) — 100.0; 99.1…
Phase 3 N=384 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Major Depressive Disorder
Primary: Change From Baseline to Week 5 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score — -11.1; -8.4; -13.0; -2.2 units on a scale — p=0.109
Phase 3 N=406 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Major Depressive Disorder
Primary: Change in Montgomery Asberg Depression Rating Scale (MADRS)-6 Score Using Average of Changes From Baseline to Week 3 Through the End of Treatment Period (Week 5 for…
Phase 3 N=66 A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Number of Subjects With Adverse Events (AEs) — 27; 28 Participants
Phase 3 N=133 The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose in Patients With Diabetes. A Randomized Control Study
Type 2 Diabetes Mellitus
Primary: Glycosylated Haemoglobin — 8.36; 8.16; 8.23; 8.53 percentage of glycosylated hemoglobin
Phase 3 N=20,869 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Dengue Fever · Dengue Hemorrhagic Fever · Dengue
Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue…
Phase 3 N=122 Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer · Neutropenia
Primary: The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo — 1.3; 3.9 days
Phase 3 N=284 Shortening Treatment by Advancing Novel Drugs
Tuberculosis, Pulmonary, Drug Sensitive · Tuberculosis, Pulmonary, Multi Drug-resistant
Primary: Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) — 38…
Phase 3 N=152 Effect of Phenazopyridine on Prolapse Surgery Voiding Trials
Urinary Retention Postoperative
Primary: Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (INTENT-TO-TREAT) — 30; 25 Participants
Phase 3 N=21 Dane County Drug Court Study for Addicted Offenders
Opioid Dependence
Primary: Number of Participants With New Crime — 5; 3 Participants
Phase 3 N=25 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Smallpox Vaccine Adverse Reaction
Primary: Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration — 52; 8; 4 percentage of participants